THYNTRA THERAPEUTICS Trademark

Pharmaceutical preparations for the treatment and prevention of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Pharmaceutical preparations for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Biological preparations for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Biologics in the nature of pharmaceutical preparations for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Biological preparations for the prevention and treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Diagnostic preparations for in vitro testing for medical use; Antibody reagents used for the detection of antigens in cells and tissue for medical purposes; Medical diagnostic reagents; Diagnostic reagents for medical use; Diagnostic agents, preparations and substances for medical purposes; Medical diagnostic reagents for use in detection, diagnosis, patient stratification, and treatment monitoring for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Diagnostic reagents for medical purposes for use in detection, diagnosis, patient stratification, and treatment monitoring for neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Antibodies for medical purposes; Therapeutic antibodies for human use for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Pharmaceutical preparations for gene therapy for the treatment of neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Drug delivery agents in the form of intranasal spray (nasal sprays), inhalation (aerosols and dry powers), oral (tables, capsules, liquids), topical (creams, gels, transdermal patches), intravenous, and intrathecal routes that facilitate the delivery of pharmaceutical preparations; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, neurological, neurodevelopmental, neurodegenerative, cardiac, pediatric, metabolic, genetic, monogenic, and rare diseases; Clinical medical reagents; Diagnostic kits comprising diagnostic agents, preparations and substances for medical purposes